Galmed Pharmaceuticals Ltd. diskutieren
Galmed Pharmaceuticals Ltd.
WKN: A1XFUX / Symbol: GMED / Name: Galmed Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
6,40 €
4,84 %
Globus Medical, Inc. (NYSE: GMED) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $100.00 price target on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target raised by analysts at Stifel Nicolaus from $80.00 to $92.00. They now have a "buy" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $100.00 price target on the stock, up previously from $83.00.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target raised by analysts at Wells Fargo & Company from $88.00 to $95.00. They now have an "overweight" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target raised by analysts at BTIG Research from $87.00 to $91.00. They now have a "buy" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target raised by analysts at Roth Mkm from $100.00 to $115.00. They now have a "buy" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target lowered by analysts at Wells Fargo & Company from $95.00 to $93.00. They now have an "overweight" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target raised by analysts at Stifel Nicolaus from $92.00 to $94.00. They now have a "buy" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target raised by analysts at Barclays PLC from $100.00 to $103.00. They now have an "overweight" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target lowered by analysts at Piper Sandler from $100.00 to $80.00. They now have an "overweight" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its "overweight" rating re-affirmed by analysts at Barclays PLC.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target lowered by analysts at Morgan Stanley from $75.00 to $68.00. They now have an "overweight" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target lowered by analysts at Wells Fargo & Company from $76.00 to $66.00. They now have an "overweight" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical (NYSE:GMED) was upgraded by analysts at Truist Financial Corporation from a "hold" rating to a "buy" rating. They now have a $93.00 price target on the stock, up previously from $65.00.
Ratings data for GMED provided by MarketBeat
Globus Medical (NYSE:GMED) was upgraded by analysts at Bank of America Corporation from a "neutral" rating to a "buy" rating. They now have a $91.00 price target on the stock, up previously from $65.00.
Ratings data for GMED provided by MarketBeat
Globus Medical (NYSE:GMED) had its price target raised by analysts at Wells Fargo & Company from $66.00 to $79.00. They now have an "overweight" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical (NYSE:GMED) had its price target raised by analysts at Royal Bank Of Canada from $88.00 to $92.00. They now have an "outperform" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical (NYSE:GMED) had its price target raised by analysts at Barclays PLC from $106.00 to $114.00. They now have an "overweight" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical (NYSE:GMED) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Ratings data for GMED provided by MarketBeat
Globus Medical (NYSE:GMED) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $105.00 price target on the stock, up previously from $93.00.
Ratings data for GMED provided by MarketBeat
Neueste Beiträge
Jefferies_Financial_ in Staar Surgical Co. diskutieren